公司治理

Search documents
石大胜华新材料集团股份有限公司 关于取消监事会并修订《公司章程》及部分治理制度的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-10-09 05:05
为贯彻落实法律法规及监管要求,进一步提升公司治理和规范运作水平,根据《公司法》《章程指引》 等相关法律、法规、规范性文件的规定,结合公司实际情况,公司将不再设置监事会和监事,监事会的 相关职权由董事会审计委员会承接行使。公司现任第八届监事会非职工代表监事高建宏先生、刘峻岭女 士职务自股东会审议通过取消监事会及修订《公司章程》事项之日起相应解除,现任职工代表监事王晓 红女士将由公司职工代表大会根据相关法律法规的规定解除其职工代表监事职务,同时公司《监事会议 事规则》等监事会相关制度相应废止。在公司股东大会审议通过取消监事会事项之前,公司第八届监事 会仍将严格按照有关法律、法规和《公司章程》的规定继续履行监督职能,维护公司和全体股东利益。 二、关于《公司章程》修订情况 基于上述取消监事会的实际情况,同时根据《公司法》《上市公司股东会规则》《章程指引》等法律法 规和规范性文件的相关规定,公司拟对《公司章程》相关条款进行修订,并提请股东大会授权公司管理 层具体办理《公司章程》及工商变更登记、章程备案等相关事宜。授权的有效期限自公司股东大会审议 通过之日起至本次相关工商变更登记及章程备案办理完毕之日止。《公司章程》修订 ...
索通发展股份有限公司关于取消监事会、修订《公司章程》及公司部分治理制度的公告
Shang Hai Zheng Quan Bao· 2025-10-08 19:36
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:603612 证券简称:索通发展 公告编号:2025-050 索通发展股份有限公司(以下简称"公司")于2025年9月30日召开的第五届董事会第二十二次会议审议 通过了《关于取消监事会、修订<公司章程>及办理工商变更登记手续的议案》和《关于修订公司部分 治理制度的议案》,于2025年9月30日召开的第五届监事会第十五次会议审议通过了《关于取消监事 会、修订<公司章程>及办理工商变更登记手续的议案》。 一、关于取消监事会的情况 为进一步规范公司运作,完善公司治理,根据《中华人民共和国公司法》《上市公司章程指引》《上市 公司治理准则》等法律法规、规章及其他规范性文件的规定,并结合实际情况,公司拟不再设置监事 会、监事,原监事会的职权由董事会审计委员会承接。在公司股东会审议通过取消监事会及修订《公司 章程》事项之前,公司现任第五届监事会仍将严格按照有关法律法规和《公司章程》的规定继续履行监 督职能,维护公司和全体股东利益。鉴于以上事项,公司拟对《公司章程》部分条款进行修订,废止 《索通发展股份有限公司监事会议事规则》,并同步修订部分治理制度。 二、《公司章 ...
金科地产集团股份有限公司关于第十一届董事会第五十九次会议决议公告
Shang Hai Zheng Quan Bao· 2025-10-08 19:27
登录新浪财经APP 搜索【信披】查看更多考评等级 证券简称:*ST金科 证券代码:000656 公告编号:2025-119号 金科地产集团股份有限公司 关于第十一届董事会第五十九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整,没有虚假记载、误导性陈述或重大遗 漏。 金科地产集团股份有限公司(以下简称"公司")于2025年9月27日以专人送达、电子邮件等方式发出关 于召开公司第十一届董事会第五十九次会议的通知,会议于2025年9月30日以通讯表决的方式召开。本 次会议由公司董事长周达先生召集并主持,应到董事7人,实到董事7人。本次会议的召集、召开和表决 程序符合有关法律、法规和《公司章程》的规定,会议形成的决议合法有效。本次会议通过如下决议: 一、审议通过《关于注销公司已回购股份暨注册资本变更的议案》 公司于2015年12月7日召开的2015年第八次临时股东大会以特别决议方式审议通过了《金科地产集团股 份有限公司限制性股票激励计划》并授权董事会全权办理本次限制性股票激励计划相关事宜。根据该激 励计划的相关规定,对不符合激励条件的限制性股票需予以回购注销。公司拟对39名不符合解锁条件的 ...
上海新华传媒股份有限公司第十届董事会第十三次会议决议公告
Shang Hai Zheng Quan Bao· 2025-10-08 19:27
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:600825 证券简称:新华传媒 编号:临2025-017 上海新华传媒股份有限公司 第十届董事会第十三次会议决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 上海新华传媒股份有限公司(以下简称"公司")于2025年9月25日向全体董事书面发出关于召开公司第 十届董事会第十三次会议的通知,并于2025年9月30日以通讯方式召开了本次会议。本次会议应参会董 事9人,实际参会董事9人。会议的召集和召开符合《公司法》和《公司章程》以及其他相关法律、法规 和规范性文件的规定。会议审议通过了如下议案并形成决议: 一、审议通过关于取消监事会并修订《公司章程》的议案 参加本项议案表决的董事9人,其中9票赞成,0票反对,0票弃权。 公司董事会同意本议案,本次《公司章程》修订完成后,公司将不再设置监事会,《公司法》中规定的 监事会的职权由董事会审计委员会行使,《上海新华传媒股份有限公司监事会议事规则》等监事会相关 制度相应废止。 本议案需提交股东大会审议。 具体内容详 ...
*ST建艺董事会会议通过多项议案,拟终止单晶硅项目合作
Xin Lang Cai Jing· 2025-10-08 07:45
2025年9月30日,*ST建艺(证券代码:002789)第五届董事会第十四次会议以联签方式召开。会议审 议通过多项议案,因市场环境变化及战略调整,拟签订《单晶硅项目投资合作终止协议》并注销建艺正 耀;为完善公司治理,将不再设监事会,其职权由董事会审计委员会行使,需提交股东大会审议修订 《公司章程》;还拟修订、制定多项内部治理制度,部分需股东大会通过后生效;此外,提议召开公司 2025年第十次临时股东大会。 ...
杉杉股份易主在即,豪门恩怨落幕,产业龙头能否重拾辉煌?
Jing Ji Guan Cha Wang· 2025-10-04 03:33
Core Viewpoint - The power struggle within the Zheng family over Shanshan Group has concluded with the company entering a restructuring process, marking a significant change in control and management, led by the new actual controller Ren Yuanlin [1][2][4]. Group 1: Control Change and Restructuring - Shanshan Group and its subsidiaries have signed a restructuring investment agreement with a consortium including Jiangsu Xinyangzi Trading, TCL Industrial Investment, and others, indicating a fundamental change in the company's control [1][4]. - The restructuring will involve the acquisition of 23.36% of Shanshan's shares through various methods, with Ren Yuanlin emerging as the new actual controller [4][5]. - The restructuring includes a strict 36-month lock-up period for all parties involved, ensuring stability in control and signaling long-term commitment to the market [5]. Group 2: Financial Performance and Challenges - Shanshan's financial performance has been declining, with net profits dropping for three consecutive years, including a loss of 367 million yuan in 2024 due to intensified industry competition and cost pressures [6][7]. - However, in the first half of 2025, Shanshan reported a net profit of 207 million yuan, a remarkable increase of 1079.59% year-on-year, attributed to stabilized prices of anode materials and optimized customer structure [7][8]. - The company's stock price has surged over 160% from its low in April 2025 to the end of September, reflecting investor confidence in the restructuring and performance recovery [9]. Group 3: Strategic Outlook and Industry Context - Shanshan has established a dual business strategy focusing on lithium battery anode materials and polarizer production, but both sectors face significant challenges [9][10]. - The new actual controller Ren Yuanlin's background in finance and investment may provide necessary support for Shanshan's strategic upgrades and industry collaboration [9][10]. - The case of Shanshan highlights the broader challenges faced by private enterprises in China regarding succession, strategic transformation, and capital operations [10].
C3.ai(AI) - 2025 FY - Earnings Call Transcript
2025-10-03 18:02
Financial Data and Key Metrics Changes - The company conducted its annual meeting and reported preliminary voting results, indicating that all proposals were approved, including the election of Class II directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2026 [10][11]. Business Line Data and Key Metrics Changes - No specific data or metrics related to individual business lines were provided in the meeting [9]. Market Data and Key Metrics Changes - No specific market data or metrics were discussed during the meeting [9]. Company Strategy and Development Direction and Industry Competition - The company is focused on maintaining strong governance through the election of directors and the approval of executive compensation, which reflects its commitment to effective management and oversight [8][10]. Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [9]. Other Important Information - The meeting was conducted virtually, and all procedures were in accordance with the company's bylaws and Delaware law [3][4]. - The company plans to disclose final voting results in a Form 8-K report to the SEC within four business days after the meeting [11]. Q&A Session Summary Question: Were there any questions submitted during the meeting? - There were no questions submitted by stockholders during the meeting [9].
C3.ai(AI) - 2025 FY - Earnings Call Transcript
2025-10-03 18:00
Financial Data and Key Metrics Changes - The company held its annual meeting to discuss various proposals and the election of directors, but specific financial data and key metrics were not disclosed during this meeting [2][4][10] Business Line Data and Key Metrics Changes - No specific data or key metrics related to individual business lines were provided in the meeting [2][4][10] Market Data and Key Metrics Changes - There was no discussion regarding market data or key metrics during the meeting [2][4][10] Company Strategy and Development Direction and Industry Competition - The meeting focused on the election of directors and the approval of executive compensation, indicating a stable governance structure, but no strategic direction or competitive analysis was presented [7][8][9] Management Comments on Operating Environment and Future Outlook - Management did not provide comments on the operating environment or future outlook during this meeting [2][4][10] Other Important Information - The meeting included the election of three Class II directors, an advisory vote on executive compensation, and the ratification of the independent accounting firm [7][8][9] - Preliminary voting results were expected to be disclosed in a Form 8-K report to the SEC within four business days after the meeting [10] Q&A Session All Questions and Answers Question: Were there any questions submitted during the meeting? - There were no questions submitted by stockholders during the meeting [8][9]
南新制药七日遭遇“三连击”:重组折戟、股东减持与监管立案下危局何解?
Jing Ji Guan Cha Wang· 2025-10-02 09:15
Core Viewpoint - Hunan Nanxin Pharmaceutical Co., Ltd. announced the termination of a major asset restructuring plan and is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report disclosure laws, indicating a challenging situation for the company in a competitive and regulated pharmaceutical industry [1][2]. Group 1: Investigation and Financial Performance - The CSRC has initiated an investigation into Nanxin Pharmaceutical due to suspected violations related to annual report disclosures, which could significantly impact investor perceptions of the company's value [2]. - The company's financial performance has shown a decline, with reported revenues of 720 million yuan in 2023, a net loss of 11 million yuan, and further losses in subsequent years, including a revenue of 263 million yuan and a net loss of 357 million yuan in 2024 [2]. - The ongoing investigation requires the company to issue monthly risk warning announcements and quarterly updates on the investigation's progress, with potential severe consequences if found guilty of major violations [2]. Group 2: Termination of Restructuring - Nanxin Pharmaceutical announced the termination of its major asset restructuring plan, which began on August 27, 2025, due to a lack of consensus on key terms among the parties involved [3]. - The company emphasized that the decision to terminate the restructuring was made to protect the interests of the company and its shareholders, and it will not adversely affect its existing business or financial status [3][4]. - The company is committed to not planning any major asset restructuring for one month following the announcement and will continue to seek investment and cooperation opportunities to enhance its product matrix and company value [4]. Group 3: Shareholder Actions - Major shareholder Guangzhou Qianyuan Investment Consulting Partnership plans to reduce its stake by up to 3% (approximately 8.232 million shares) starting October 27, 2025, due to funding needs [5]. - The shareholder currently holds 43.12 million shares, representing a 15.71% stake, and previously made a commitment not to transfer shares within 12 months of the company's IPO [5][6]. - The combination of the investigation, termination of restructuring, and shareholder reduction may negatively impact market expectations and investor confidence in the company [6].
这几大银行为何撤销监事会
Jing Ji Ri Bao· 2025-10-01 22:13
Core Viewpoint - The decision by five major state-owned commercial banks in China to abolish the supervisory board is aimed at enhancing corporate governance flexibility and effectiveness while reducing management costs [1][2]. Group 1: Corporate Governance Changes - The abolishment of the supervisory board does not weaken internal supervision but instead allows the audit committee of the board of directors to assume the responsibilities previously held by the supervisory board, thereby strengthening internal checks and balances [1][2]. - The new Company Law, effective from July 1, 2024, introduces new requirements regarding the supervisory board and employee directors, allowing financial institutions to optimize their supervisory structures based on their actual circumstances [1][2]. Group 2: Implications for Financial Institutions - Financial institutions must continue to improve corporate governance and enhance internal supervision efficiency to support high-quality financial development [3]. - Institutions that choose to have the audit committee perform the supervisory board's duties must follow relevant corporate governance procedures, including amending articles of association and personnel selection [3]. - There is a focus on strengthening the management of related party transactions and improving the effectiveness of board operations to prevent risks associated with interest transfers and ensure sound operations [3].